DRG Market Assessment reports

Renal cell carcinoma (RCC) is a disease characterized by significant unmet need and, thus, opportunity. Its incidence is increasing in the major pharmaceutical markets, and many patients with early…

Last Updated 2 October 2014 The sizable therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand. The prevalence…

With a large and growing patient population, asthma is one of the most lucrative drug markets in the pharmaceutical industry. Maintenance treatments for persistent asthma include inhaled…

Last Updated 1 October 2014 The market for Alzheimer’s disease (AD) pharmacotherapies continues to offer compelling commercial opportunities driven by considerable unmet need. The AD population…

Benlysta (GlaxoSmithKline) is not only the first drug approved for systemic lupus erythematosus (SLE) in more than 50 years, but also the first biologic approved for the indication. However, uptake…

Last Updated 29 September 2014 Treatment options for Crohn’s disease (CD) include conventional, largely generic small molecules and more-potent biological agents, including tumor necrosis…

Last Updated 29 September 2014 Parkinson’s disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly, and its prevalence is expected to grow 2% annually as the…

Recent changes in the US healthcare system are having a profound and transformational impact on the medical technology industry. As manufacturers face challenges to the traditional business model…

Heart failure describes a pathophysiological state in which the heart is unable to efficiently supply the body with oxygenated blood in order to meet the body’s metabolic demands. While acute…

The asthma market has historically been one of the most lucrative drug markets in the pharmaceutical industry owing to a large and growing patient population. However, generic and/or branded-…

TreatmentTrends®: Rheumatoid Arthritis 2014 (US) explores the use of conventional DMARDs as well as biologics or Xeljanz for the treatment of rheumatoid arthritis (RA). One hundred U.S…

Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as varied as…